Portal de Periódicos da CAPES

A Short Overview of Resistance to Approved Histone Deacetylase Inhibitors

2021; Future Science Ltd; Volume: 13; Issue: 14 Linguagem: Inglês

10.4155/fmc-2021-0102

1756-8927

Fabian Fischer, Leandro A. Alves Avelar,

Peptidase Inhibition and Analysis

Future Medicinal ChemistryVol. 13, No. 14 EditorialA short overview of resistance to approved histone deacetylase inhibitorsFabian Fischer & Leandro A Alves AvelarFabian Fischer https://orcid.org/0000-0003-1140-2024Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf, Universitätsstr. 1, Düsseldorf, 40225, Germany & Leandro A Alves Avelar *Author for correspondence: E-mail Address: leandro.alves.avelar@uni-duesseldorf.dehttps://orcid.org/0000-0001-7394-3286Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf, Universitätsstr. 1, Düsseldorf, 40225, GermanyPublished Online:7 May 2021https://doi.org/10.4155/fmc-2021-0102AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: cancer resistancecancer therapyepigeneticshistone deacetylasesReferences1. Ho TCS, Chan AHY, Ganesan A. Thirty years of HDAC inhibitors: 2020 insight and hindsight. J. Med. Chem. 63(21), 12460–12484 (2020).Crossref, Medline, CAS, Google Scholar2. Feng S, De Carvalho DD. Clinical advances in targeting epigenetics for cancer therapy. FEBS J. 1–26 (2021).Google Scholar3. Lu X, Ning Z, Li Z, Cao H, Wang X. Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China. Intractable Rare Dis. Res. 5(3), 185–191 (2016).Crossref, Medline, Google Scholar4. Hontecillas-Prieto L, Flores-Campos R, Silver A, de Álava E, Hajji N, García-Domínguez DJ. Synergistic enhancement of cancer therapy using HDAC inhibitors: opportunity for clinical trials. Front. Genet. 11, 578011 (2020).Crossref, Medline, CAS, Google Scholar5. Suraweera A, O'Byrne KJ, Richard DJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front. Oncol. 8, 1–15 (2018).Crossref, Medline, Google Scholar6. Quagliano A, Gopalakrishnapillai A, Barwe SP. Understanding the mechanisms by which epigenetic modifiers avert therapy resistance in cancer. Front. Oncol. 10, 1–14 (2020).Crossref, Medline, Google Scholar7. Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature 575(7782), 299–309 (2019).Crossref, Medline, CAS, Google Scholar8. Ward RA, Fawell S, Floc'h N, Flemington V, Mckerrecher D, Smith PD. Challenges and opportunities in cancer drug resistance. Chem. Rev. 121(6), 3297–3351 (.2020).Crossref, Medline, Google Scholar9. Robey RW, Chakraborty AR, Basseville A et al. Histone deacetylase inhibitors: emerging mechanisms of resistance. Mol. Pharm. 8(6), 2021–2031 (2011).Crossref, Medline, CAS, Google Scholar10. Lee JH, Choy ML, Marks PA. Mechanisms of Resistance to Histone Deacetylase Inhibitors (1st Edition). Elsevier Inc, Amsterdam, The Netherlands (2012).Google Scholar11. Rana Z, Diermeier S, Hanif M, Rosengren RJ. Understanding failure and improving treatment using HDAC inhibitors for prostate cancer. Biomedicines 8(2), 22 (2020).Crossref, CAS, Google Scholar12. Lee JH, Choy ML, Ngo L, Venta-Perez G, Marks PA. Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 108(49), 19629–19634 (2011).Crossref, Medline, CAS, Google Scholar13. Li Y, Liu Y, Zhao N et al. Checkpoint regulator B7x is epigenetically regulated by HDAC3 and mediates resistance to HDAC inhibitors by reprogramming the tumor immune environment in colorectal cancer. Cell Death Dis. 11(9), 753 (2020).Crossref, Medline, CAS, Google Scholar14. Mrakovcic M, Fröhlich LF. Molecular determinants of cancer therapy resistance to HDAC inhibitor-induced autophagy. Cancers (Basel) 12(1), 1–30 (2020).Google Scholar15. Berghauser Pont LME, Spoor JKH, Venkatesan S et al. The BCL-2 inhibitor obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells. Genes and Cancer. 5(11-12), 445–459 (2014).Crossref, Medline, Google Scholar16. Zeng H, Qu J, Jin N et al. Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylase inhibitors in breast cancer. Cancer Cell 30(3), 459–473 (2016).Crossref, Medline, CAS, Google Scholar17. Liang X, Zang J, Li X et al. Discovery of novel janus kinase (JAK) and histone deacetylase (HDAC) dual inhibitors for the treatment of hematological malignancies. J. Med. Chem. 62(8), 3898–3923 (2019).Crossref, Medline, CAS, Google Scholar18. Lee SC, Min HY, Jung HJ et al. Essential role of insulin-like growth factor 2 in resistance to histone deacetylase inhibitors. Oncogene 35(42), 5515–5526 (2016).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByDesigning HDAC-PROTACs: lessons learned so farFabian Fischer, Leandro A Alves Avelar, Laoise Murray & Thomas Kurz24 December 2021 | Future Medicinal Chemistry, Vol. 14, No. 3 Vol. 13, No. 14 Follow us on social media for the latest updates Metrics Downloaded 101 times History Received 12 April 2021 Accepted 22 April 2021 Published online 7 May 2021 Published in print July 2021 Information© 2021 Newlands PressKeywordscancer resistancecancer therapyepigeneticshistone deacetylasesFinancial & competing interests disclosureThe authors would like to thank the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) and the Research Training Group GRK 2158. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download